Theravance Biopharma
TBPH
108 hedge funds and large institutions have $1.16B invested in Theravance Biopharma in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 28 reducing their positions, and 8 closing their positions.
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
29% more capital invested
Capital invested by funds: $900M → $1.16B (+$260M)
18% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 28
17% more funds holding
Funds holding: 92 → 108 (+16)
2.59% less ownership
Funds ownership: 81.55% → 78.97% (-2.6%)
45% less call options, than puts
Call options by funds: $726K | Put options by funds: $1.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$61.8M |
| 2 |
C
Chescapmanager
Baltimore,
Maryland
|
+$6.83M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.37M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$2.33M |
| 5 |
NM
Newtyn Management
New York
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.84M |
| 2 |
3C
361 Capital
Denver,
Colorado
|
-$2.52M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.34M |
| 4 |
Squarepoint
New York
|
-$967K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$722K |
TBPH Hedge Fund Activity: Q4 2019 in Review
108 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2019, worth a combined $1.16B — up 29% from $900M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new TBPH positions and 8 closed out — a net gain of 21 holders — while 33 added to existing stakes and 28 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $61.8M. The largest seller was UBS Group, cutting an estimated $3.84M.
- 108 institutional investors held Theravance Biopharma (TBPH) as of Q4 2019, up from 92 in Q3 2019.
- Funds reported $1.16B of Theravance Biopharma stock for Q4 2019, up 29% quarter-over-quarter.
- 29 funds opened new Theravance Biopharma positions in Q4 2019 and 8 closed out, a net change of +21 holders.
- The largest Theravance Biopharma buyer in Q4 2019 was Wellington Management Group, an estimated $61.8M added.
- The largest Theravance Biopharma seller in Q4 2019 was UBS Group, an estimated $3.84M sold.
Based on aggregated 13F filings for Q4 2019.